HeartFlow Chief Financial Officer Acquires Stock and Options in Company Transaction

Details of the Common Stock Acquisition

The disclosure reveals that Verghese completed an acquisition of 22,522 shares of HeartFlow common stock on July 27, 2026. The purchase price was set at $2.22 per share, representing a direct transaction in the company's equity. Following this acquisition, Verghese's direct beneficial ownership of common stock rose to 255,898 shares, demonstrating a material stake in the company's future performance and direction.

The common stock purchase constitutes a direct beneficial ownership position, meaning Verghese holds the shares outright without any intermediate ownership structure. This direct holding is particularly relevant to investors analyzing insider sentiment, as executive purchases of company equity at prevailing market prices may indicate management's belief in valuation or company prospects. The filing provides no information regarding whether this purchase was made under an established trading plan or represented a discretionary personal investment decision.

Stock Options and Vesting Schedule

In addition to the common stock purchase, the filing discloses that Verghese received stock options to acquire 22,522 shares of common stock at an exercise price of $2.22 per share. These options were granted on the same transaction date, July 27, 2026, and carry an expiration date of December 24, 2033. The options represent a derivative security interest that becomes valuable if the underlying common stock appreciates above the exercise price.

The options are subject to a vesting schedule that extends through October 30, 2027. According to the disclosure, the options vest and become exercisable in monthly installments, conditional upon Verghese's continued service with HeartFlow through each applicable vesting date. Following this grant, Verghese holds 66,588 options in beneficial ownership. This vesting structure is typical for equity compensation arrangements designed to align executive interests with long-term company performance and employee retention.

Significance of Executive Equity Participation

Insider stock acquisitions and option grants serve as important data points for investors evaluating management alignment with shareholder interests. When a company's Chief Financial Officer purchases shares at market rates—as disclosed in this transaction at $2.22 per share—it may signal confidence in the company's strategic direction or valuation. Such transactions are public record precisely because regulators and investors view executive equity purchases as potentially informative about internal perspectives on company value.

The combination of common stock acquisition and option grants creates a layered incentive structure. The immediate common stock purchase represents a sunk capital commitment, while the vesting options provide long-term upside participation. This dual approach is consistent with compensation philosophies that seek to balance near-term financial commitment with extended-period performance alignment. However, investors should note that option grants as part of executive compensation may be routine and scheduled, rather than discretionary purchases reflecting changed strategic views.

Beneficial Ownership Position Following Transaction

Following the July 27, 2026 transaction, the filing documents Verghese's cumulative beneficial ownership across both direct equity and derivative securities. The CFO's direct beneficial ownership of common stock stands at 255,898 shares, representing a material ownership interest in HeartFlow. This position places Verghese among the company's significant individual shareholders, though the disclosure does not compare this holding to the company's total outstanding shares or percentages.

The derivative securities position adds another layer to Verghese's economic interest in company performance. With 66,588 options now beneficially owned—including the 22,522 options granted in this transaction—Verghese has substantial potential to acquire additional shares upon exercise. The cumulative position reflects an executive with substantial personal financial exposure to HeartFlow's stock price performance, which may be viewed as enhancing alignment between executive decision-making and shareholder wealth creation.

Transaction Execution and Reporting Timeline

The transaction occurred on July 27, 2026, with the ownership change disclosure filed one business day later on July 28, 2026. This rapid reporting reflects the regulatory requirement that officers of publicly traded companies file beneficial ownership changes within two business days of transaction execution. The filing was executed on behalf of Verghese by Nga Van, acting under power of attorney, as indicated by the signature line on the disclosure form.

The precise dating and rapid reporting ensure that public investors have timely access to information about executive trading activity. The disclosure includes both the transaction date and the filing date, allowing investors to verify the timeliness of the reporting. No amendment or correction to this filing has been indicated, suggesting that the disclosed transaction details are final and complete as of the filing date.

Exercise Price and Market Context

Both the common stock purchase and the stock option grant were executed at $2.22 per share. The use of identical pricing for both the equity acquisition and the derivative security exercise price indicates that the options were granted at-the-money—meaning the exercise price equals the fair market value of the stock on the grant date. This pricing structure aligns the options' potential value creation with stock appreciation beyond the current market price, a standard practice in equity compensation design.

The $2.22 pricing point is documented in the filing but should be understood within broader context of HeartFlow's trading history and market conditions, which the disclosure does not address. Investors seeking to understand the significance of this price relative to historical trading ranges or peer valuations would need to consult additional market data and analysis beyond the scope of this regulatory filing.

Officer Title and Reporting Obligations

The filing explicitly identifies Verghese as Chief Financial Officer of HeartFlow, Inc., placing him among the company's senior executive officers subject to Section 16 reporting obligations under federal securities law. Officers, directors, and 10 percent beneficial owners of publicly traded companies must disclose changes in their ownership of company securities, making this transaction disclosure a legal requirement rather than a voluntary disclosure.

The fact that Verghese is required to file such disclosures reflects his role as an insider with potential access to material nonpublic information about HeartFlow. Regulatory framework requires these disclosures to prevent abuse of information asymmetries and to provide the investing public with transparent information about executive behavior. The disclosure demonstrates that HeartFlow maintains appropriate compliance with insider reporting requirements.

Nature of Ownership and Investment Form

The filing indicates that Verghese holds the 255,898 common shares in direct beneficial ownership form, meaning he retains personal title and control over the equity. The options are similarly held in direct form, though they represent conditional future rights rather than immediate ownership. This direct beneficial ownership structure is distinct from situations where an insider holds shares through trusts, family partnerships, or other indirect structures, which would require disclosure of the nature of the indirect ownership.

Direct beneficial ownership simplifies the insider's relationship with the underlying equity and provides clear visibility to the investing public regarding the extent of management's personal financial commitment. The filing provides no indication of any pledges, loans, or other encumbrances on the shares held by Verghese, which would be required to be disclosed if applicable.

Investor Considerations and Information Limitations

The immediate share price impact was not clear from available public information contained in this disclosure. The filing documents what occurred—the transaction details, timing, and resulting ownership positions—but does not provide analysis of market reaction or trading context. Investors interested in understanding how markets responded to this insider transaction would need to consult contemporaneous market data and trading records.

Additionally, the filing does not explain the business purpose or rationale behind the transaction, nor does it indicate whether the equity acquisition and option grant were part of a prearranged compensation plan or represented discretionary executive decisions. While Section 16 filings provide transparent documentation of ownership changes, they are limited in scope to factual transaction details and do not typically include executive commentary on motivations or strategic implications. Investors seeking deeper context may review company proxy statements, compensation committee reports, or management commentary in quarterly and annual filings.